Business Standard

Moved imp products out of Mohali, Dadra plants: Sun Pharma's Abhay Gandhi

Speaking to Sohini Das over a video interview from the US, Abhay Gandhi, CEO, North America of Sun Pharma outlines his plan for the company's specialty business

Abhay Gandhi
Premium

Abhay Gandhi, CEO, North America Business, Sun Pharma

Sohini Das Mumbai

Listen to This Article

Sun Pharmaceutical Industries has guided for high single-digit top line growth in FY25, and higher R&D spend as it enters an investment phase for developing its product pipeline. Speaking to Sohini Das in a video interview from the US, Abhay Gandhi, CEO, North America Business, outlines the plan for the company’s specialty business. Edited excerpts.

The specialty business hit the $1 billion milestone in FY24. What is the outlook?

We are excited that for the first time the global specialty business has crossed the $1 billion mark in FY24. That is a significant milestone for us and something we aspired

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in